RNA

IVBH Presents Groundbreaking Data for Early Lung Cancer Detection at the ASCO® 2023 Annual Meeting

Retrieved on: 
Friday, June 2, 2023
Surgical oncology, Liquid biopsy, Lung cancer, RNA, Cardiothoracic surgery, Professor, Patient, Machine learning, Annual general meeting, Neoplasm, Poster, Disease, Vaccine, Medical imaging

NEWPORT BEACH, Calif., June 2, 2023 /PRNewswire/ -- IVBH, a leader in liquid biopsy technology, specializing in noninvasive early detection, will unveil groundbreaking data from an independent validation study of the company's proprietary LiquidLung lung cancer detection technology, at the ASCO® 2023 Annual Meeting. This study of 3,744 subjects, including patients with pre-operative lung cancer and non-cancer controls, demonstrated accurate detection of early-stage lung cancer across prevalent histologic types and subgroups of patients with lung cancer, including never-smokers.

Key Points: 
  • IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort
    NEWPORT BEACH, Calif., June 2, 2023 /PRNewswire/ -- IVBH, a leader in liquid biopsy technology, specializing in noninvasive early detection, will unveil groundbreaking data from an independent validation study of the company's proprietary LiquidLung lung cancer detection technology, at the ASCO® 2023 Annual Meeting.
  • This study of 3,744 subjects, including patients with pre-operative lung cancer and non-cancer controls, demonstrated accurate detection of early-stage lung cancer across prevalent histologic types and subgroups of patients with lung cancer, including never-smokers.
  • This peer-reviewed research represents a significant step forward in the early detection of lung cancer.
  • "Traditionally, the liquid biopsy field has focused on detecting cancer cells shed into the bloodstream by a tumor," said Marty Keiser, IVBH Founder-CEO.

Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

Retrieved on: 
Friday, June 2, 2023
Vaccine, Diversified Specialty Institute Holdings, Inc., Partnership, Therapy, Newsweek, Science Policy Research Unit, MBA, Research, Infection, RNA, Messenger, Government, University Health Network, UHN, Hospital, Patient, PTX-COVID19-B, Child, Cancer, Diagnosis, Pharmaceutical industry, Science

This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.

Key Points: 
  • This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.
  • “This partnership is unique in that it provides country-of-origin rights to Canada for all therapies developed under the agreement.
  • “UHN is world-class, and Providence has demonstrated its mRNA platform is on par with other major mRNA companies.
  • This sets up Canada to be a leader in exporting life-saving therapies throughout the world while taking care of Canadians.”
    Brad Wouters, Executive Vice President, Science and Research at the University Health Network added, “Our partnership with Providence demonstrates the strength of discovery research at the University Health Network and our potential to fuel innovative therapeutic options for patients.

EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics

Retrieved on: 
Friday, June 2, 2023
Vaccine, Human, Therapy, Hendra virus, Nipah virus, Frankfurt Stock Exchange, Global health, Research, RNA, Hendra, Open Philanthropy (organization), Henipavirus, ISIN, World Health Organization, R, EVO

Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.
  • Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses.
  • The genus comprises six different established species including Hendra virus and Nipah virus, from which it receives its name.
  • This is the first time that we have been supported by Open Philanthropy and we are very excited about this opportunity.

Oncorus Announces Workforce Reduction Plan

Retrieved on: 
Thursday, June 1, 2023
Workforce, Cancer, Acquisition, Patient, RNA, Management

ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus’ workforce, which is expected to be completed by August 2023.

Key Points: 
  • ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus’ workforce, which is expected to be completed by August 2023.
  • Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (Chief Operating Officer and Chief of Staff), and John M. Goldberg, M.D.
  • (Chief Medical Officer) will be departing the Company as part of the workforce reduction, with such transition date expected to be no later than June 30, 2023.
  • Despite cost-savings measures associated with the workforce reduction, the Company anticipates that its existing cash and projected cash flows will not be sufficient to meet its working capital and operational needs beyond the third quarter of 2023.

BostonGene Announces Six Abstract Acceptances at the 2023 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Oncology, Health, Technology, Health Insurance, Clinical Trials, Artificial Intelligence, IDC, Abstract, ICI, American Journal of Clinical Oncology, Sarcoma, RNA-Seq, Cancer, Research, Monroe Dunaway Anderson, Neoplasm, Biomarker, RNA, Immunotherapy, ASCO, GATA3, Journal, MD, Patient, Sequence, TME, Weill Cornell Medicine, WES, Tumor microenvironment, Breast cancer, ILC, Medical imaging, Vaccine

“We look forward to sharing results from our research analyzing genomic and transcriptomic classifications and our analysis demonstrating the added benefit of comprehensive genomic profiling in a thousand diverse cancer patients at the 2023 ASCO Annual Meeting.

Key Points: 
  • “We look forward to sharing results from our research analyzing genomic and transcriptomic classifications and our analysis demonstrating the added benefit of comprehensive genomic profiling in a thousand diverse cancer patients at the 2023 ASCO Annual Meeting.
  • These presentations reflect our scientific expertise and commitment to bringing innovative solutions into clinical practice,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • For more information, please visit the 2023 ASCO Annual Meeting website .
  • The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, FDA, Health, Genetics, Pharmaceutical, Vaccine, Acceleration, Biologics license application, FCP, Diversified Specialty Institute Holdings, Inc., Therapy, Arcturus Therapeutics, Infection, ARCT, MBA, Medicine, RNA, MD, OTC, Liver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Arcturus

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
  • Fast Track Designation is designed to facilitate development and expedite review of new therapeutics intended to treat serious or life-threatening conditions that demonstrate the potential to address important unmet medical needs.
  • Programs granted Fast Track Designation may receive important benefits including more frequent interactions with FDA review teams and the ability to obtain rolling review of a Biologics License Application (BLA).
  • “ARCT-810 has the potential to be an important new medicine for individuals living with OTC deficiency and we are very pleased to have obtained Fast Track Designation for this program.

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products

Retrieved on: 
Thursday, June 1, 2023
Unified Patent Court, Federal Patent Court (Germany), NanoString Technologies, Genomics, SMI, UPC, RNA, Judgement, Patent, Microscope, EU

PLEASANTON, Calif., June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it filed new patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and Vizgen, Inc. in the European Unified Patent Court. 

Key Points: 
  • 10x Genomics' new lawsuits allege that the use and distribution of NanoString's CosMx products for RNA detection infringe European Patents 2 794 928 B1 ("the EP 928 patent") and 4 108 782 B1 ("the EP 782 patent").
  • 10x Genomics also filed suit against Vizgen's MERSCOPE products for infringement of the EP 782 patent.
  • In its new lawsuits against NanoString before the Munich Local Division of the Unified Patent Court, 10x Genomics is seeking preliminary injunctions against NanoString's CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in the jurisdictions of the Unified Patent Court in which the EP 928 and EP 782 patents are in effect.
  • In February 2023, the German Federal Patent court issued a preliminary opinion finding the asserted claims of the EP 928 patent valid.

BIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference

Retrieved on: 
Thursday, June 1, 2023
Rapunzel's Tangled Adventure (season 2), Drug discovery, Pathology, ALS, RNA, DSM-IV codes, CNS, Central nervous system, Small RNA, Central nervous system disease, Amyloid, Parkinson's disease, Myenteric plexus, ASO, RNA interference, NHP, FDA, IND, Alzheimer's disease, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Nanomedicine, Brain

ET, Room 104A

Key Points: 
  • ET, Room 104A
    Drug delivery platform expanded to previously inaccessible neurological diseases, including brain cancers
    CAMBRIDGE, Mass.
  • The conference, the largest in the industry, is scheduled for June 5 - 8, 2023, in Boston.
  • Ahead of engagements with the FDA regarding an Investigational New Drug (IND) pathway, the company expects to complete IND enabling work in 2024.
  • Today's results further strengthen BMD-001 within our neurodegenerative diseases franchise targeting Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease."

Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988

Retrieved on: 
Wednesday, May 31, 2023
Cocrystal, SARS-CoV-2, Coronavirus, COVID-19, Pharmacokinetics, RNA, Government, Patient, Orthornavirae, CFO, Safety, COCP, Pharmaceutical industry, Vaccine

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces approval from the Australian Human Research Ethics Committee (HREC) to conduct a Phase 1 study with its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a potential treatment for COVID-19.

Key Points: 
  • BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces approval from the Australian Human Research Ethics Committee (HREC) to conduct a Phase 1 study with its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a potential treatment for COVID-19.
  • The Phase 1 randomized, double-blind, placebo-controlled, dose-escalating study will assess the safety, tolerability and pharmacokinetics of CDI-988 in healthy volunteers.
  • CDI-988 exhibited superior in vitro potency against SARS-CoV-2 and other coronaviruses, and demonstrated a favorable safety profile and pharmacokinetic properties supportive of daily oral dosing.
  • Cocrystal applied its proprietary drug discovery platform technology to design this investigational drug candidate.